📣 VC round data is live. Check it out!
- Public Comps
- Rigel Pharmaceuticals
Rigel Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Rigel Pharmaceuticals and similar public comparables like Pharmicell, Valneva, Altimmune, Boiron and more.
Rigel Pharmaceuticals Overview
About Rigel Pharmaceuticals
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Founded
1996
HQ

Employees
164
Website
Financials (LTM)
EV
$456M
Valuation Multiples
Start free trialRigel Pharmaceuticals Financials
Rigel Pharmaceuticals reported last 12-month revenue of $284M and EBITDA of $95M.
In the same LTM period, Rigel Pharmaceuticals generated $264M in gross profit, $95M in EBITDA, and $238M in net income.
Revenue (LTM)
Rigel Pharmaceuticals P&L
In the most recent fiscal year, Rigel Pharmaceuticals reported revenue of $294M and EBITDA of $132M.
Rigel Pharmaceuticals is profitable as of last fiscal year, with gross margin of 93%, EBITDA margin of 45%, and net margin of 125%.
Financial data powered by Morningstar, Inc.
Rigel Pharmaceuticals Stock Performance
Rigel Pharmaceuticals has current market cap of $557M, and enterprise value of $456M.
Market Cap Evolution
Rigel Pharmaceuticals' stock price is $30.08.
Rigel Pharmaceuticals share price decreased by 1.3% in the last 30 days, and increased by 60.6% in the last year.
Rigel Pharmaceuticals has an EPS (earnings per share) of $19.84.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $456M | $557M | 0.8% | -1.3% | 11.2% | 60.6% | $19.84 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRigel Pharmaceuticals Valuation Multiples
Rigel Pharmaceuticals trades at 1.6x EV/Revenue multiple, and 4.8x EV/EBITDA.
EV / Revenue (LTM)
Rigel Pharmaceuticals Financial Valuation Multiples
As of June 3, 2026, Rigel Pharmaceuticals has market cap of $557M and EV of $456M.
Rigel Pharmaceuticals has a P/E ratio of 2.3x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Rigel Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Rigel Pharmaceuticals Margins & Growth Rates
Rigel Pharmaceuticals decreased revenue by 8% and EBITDA by 61% in the last fiscal year.
In the most recent fiscal year, Rigel Pharmaceuticals reported gross margin of 93%, EBITDA margin of 45%, and net margin of 125%.
Rigel Pharmaceuticals Margins
Rigel Pharmaceuticals Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Rigel Pharmaceuticals Operational KPIs
Rigel Pharmaceuticals' revenue per employee in the last FY averaged $1.8M, while opex per employee averaged $0.9M for the same period.
Rigel Pharmaceuticals' Rule of 40 is 11% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Rigel Pharmaceuticals' Rule of X is (2%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Rigel Pharmaceuticals Competitors
Rigel Pharmaceuticals competitors include Pharmicell, Valneva, Altimmune, Boiron, Avalon Pharma, Gyre Therapeutics, enGene, Ironwood Pharmaceuticals, Nika Pharmaceuticals and Nxera Pharma.
Most Rigel Pharmaceuticals public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 6.9x | 5.9x | 20.6x | 16.5x | |||
| 3.3x | 3.5x | (11.5x) | (11.9x) | |||
| 6543.5x | 10372.9x | (3.1x) | (2.5x) | |||
| 0.9x | - | 7.0x | - | |||
| 4.7x | 4.5x | 16.8x | 15.6x | |||
| 4.2x | 4.5x | 35.2x | (170.9x) | |||
| - | - | - | - | |||
| 3.1x | 2.5x | 6.6x | 4.3x | |||
This data is available for Pro users. Sign up to see all Rigel Pharmaceuticals competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Rigel Pharmaceuticals
| When was Rigel Pharmaceuticals founded? | Rigel Pharmaceuticals was founded in 1996. |
| Where is Rigel Pharmaceuticals headquartered? | Rigel Pharmaceuticals is headquartered in United States. |
| How many employees does Rigel Pharmaceuticals have? | As of today, Rigel Pharmaceuticals has over 164 employees. |
| Who is the CEO of Rigel Pharmaceuticals? | Rigel Pharmaceuticals' CEO is Raul R. Rodriguez. |
| Is Rigel Pharmaceuticals publicly listed? | Yes, Rigel Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Rigel Pharmaceuticals? | Rigel Pharmaceuticals trades under RIGL ticker. |
| When did Rigel Pharmaceuticals go public? | Rigel Pharmaceuticals went public in 2000. |
| Who are competitors of Rigel Pharmaceuticals? | Rigel Pharmaceuticals main competitors include Pharmicell, Valneva, Altimmune, Boiron, Avalon Pharma, Gyre Therapeutics, enGene, Ironwood Pharmaceuticals, Nika Pharmaceuticals, Nxera Pharma. |
| What is the current market cap of Rigel Pharmaceuticals? | Rigel Pharmaceuticals' current market cap is $557M. |
| What is the current revenue of Rigel Pharmaceuticals? | Rigel Pharmaceuticals' last 12 months revenue is $284M. |
| What is the current revenue growth of Rigel Pharmaceuticals? | Rigel Pharmaceuticals revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Rigel Pharmaceuticals? | Current revenue multiple of Rigel Pharmaceuticals is 1.6x. |
| What is the current EBITDA of Rigel Pharmaceuticals? | Rigel Pharmaceuticals' last 12 months EBITDA is $95M. |
| What is Rigel Pharmaceuticals' EBITDA margin? | Rigel Pharmaceuticals' last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of Rigel Pharmaceuticals? | Current EBITDA multiple of Rigel Pharmaceuticals is 4.8x. |
| How many companies Rigel Pharmaceuticals has acquired to date? | Rigel Pharmaceuticals hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Rigel Pharmaceuticals has invested to date? | Rigel Pharmaceuticals hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Rigel Pharmaceuticals
Lists including Rigel Pharmaceuticals
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.